Compare iShares International Treasury Bond ETF (IGOV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs ResMed Inc. — how do they compare? iShares International Treasury Bond ETF trades at $41.2, while ResMed Inc. trades at $225.38 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| IGOV | RMD | |
|---|---|---|
52-Week High | $43.09 | $293.73 |
52-Week Low | $40.35 | $182.82 |
Market Cap | — | $32.61B |
Sector | — | Health |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $41.13, down 0.15% on the day, with a bullish technical signal driven by moving averages despite neutral oscillators. The stock shows consolidated trading near key support at $41. Financial data remains limited, but recent news highlights significant exposure to global bond market volatility through its ETF structure.
The outlook is clouded by interest rate sensitivity and inflationary pressures, posing downside risks. Investment appeal hinges on macroeconomic stability, while the primary opportunity lies in potential yield curve normalization benefiting long-duration assets.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
